Clinical trials: Transplantation
Kidney Transplantation
Safety and Tolerance of Increased Doses of SHR-2106 Injection in Healthy Subjects
This is a randomized, double-blind, placebo-controlled phase I clinical study with the primary objective of evaluating the safety and tolerability of SHR-2106 in healthy subjects after a single intravenous or subcutaneous…
- Trial name
- NCT05948059
- Where
- China
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Guangdong Hengrui Pharmaceutical Co., Ltd
Androgenetic Alopecia, Alopecia
THERAVEX® REGENERA Tissue Care Plus for Hair Regeneration and Follicular Microenvironment Modulation
To evaluate the safety and clinical performance of THERAVEX® REGENERA Tissue Care Plus as an adjunctive regenerative support therapy in patients undergoing hair restoration procedures and regenerative scalp treatment protocols.
- Conditions
- Androgenetic Alopecia, Alopecia, Hair Loss, Non-scarring Alopecia
- Trial name
- NCT07615608
- Testing
- Standard Hair Restoration Care
- Where
- Spain
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Biointelligent Technology Systems SL
Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS)
Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics
This study aim is to assess, if treosulfan pharmacokinetics are influenced by declined renal function and by race/ethnicity of patients.
- Conditions
- Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
- Trial name
- NCT05534620
- Testing
- Treosulfan, Fludarabine
- Where
- 3 sites in United States
- Volunteers
- 20 people
- Sponsor
- medac GmbH
Kidney Transplantation in Highly Sensitized Patients
Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
An open-label post authorization efficacy and safety study evaluating graft failure-free survival at 1-year in highly sensitized end-stage renal disease (ESRD) patients with positive crossmatch (XM) against a deceased donor prior…
- Trial name
- PAES (NCT05369975)
- Testing
- Imlifidase, Normal Transplantation Routine
- Where
- 22 sites in Austria, Belgium and 9 more
- Volunteers
- 113 people
- Sponsor
- Hansa Biopharma AB
Renal Transplantation
A Study of TCD601 in de Novo Renal Transplant Recipients
The purpose of this study is to evaluate the safety and efficacy of TCD601 in combination with Belatacept when compared to standard of care immunosuppression therapy in de novo renal transplant patients.
- Trial name
- ASCEND (NCT05669001)
- Testing
- TCD601, belatacept, ATG
- Where
- 18 sites in United States
- Volunteers
- 76 people
- Sponsor
- ITB-Med LLC
Kidney Transplantation in Highly Sensitized Patients
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx
An open-label, controlled, randomized Phase 3 trial evaluating 12-month kidney function in highly sensitized (cPRA ≥99.9%) kidney transplant patients with positive crossmatch against a deceased donor, comparing desensitization…
- Trial name
- ConfIdeS (NCT04935177)
- Testing
- Imlifidase, PLEX, IVIg
- Where
- 25 sites in United States
- Volunteers
- 64 people
- Sponsor
- Hansa Biopharma AB
Kidney Transplantation
REgulatory T Cell Therapy to Achieve Immunosuppression REduction
The goal of this multi-national, multi-center, open-label, randomized Phase 2 trial is to determine the safety and efficacy of administering expanded regulatory T cells (TRK-001) to prevent allograft rejection in living donor…
- Trial name
- RETIRE (NCT06552169)
- Testing
- Arm 1: SOC (mTOR + CNI), Arm 2A: TRACT/MONO mTOR, Arm 2B: TRACT/MONO CNI
- Where
- 7 sites in United States, Taiwan
- Volunteers
- 34 people
- Sponsor
- Singulera Therapeutics Inc.
Heart Transplantation
Non-ischemic Preservation of the Donor Heart in Heart Transplantation
The study intends to compare standard ischemic cold static storage (ICSS) of retrieved hearts intended to be transplanted, to non-ischemic heart preservation (NIHP) in a randomized clinical multicentre trial.
- Trial name
- NCT03991923
- Testing
- XVIVO heart preservation devices, Standard ICSS
- Where
- 15 sites in Austria, Belgium and 6 more
- Volunteers
- 230 people
- Sponsor
- XVIVO Perfusion
Cytomegalovirus Infection, Hematopoietic Stem Cells Transplantation
Burden of Cytomegalovirus Reactivation in Pediatric Patients After Allogeneic Hematopoietic Stem Cell Transplantation
This observational retrospective analysis will provide useful information for clinicians and payers, and local guidelines committee members, to improve the understanding of Cytomegalovirus clinical and economic burden and…
- Trial name
- CMV PED (NCT06916195)
- Where
- 5 sites in Italy
- Volunteers
- 230 people
- Sponsor
- MSD Italia S.r.l.
ESRD (End-Stage Renal Disease), Kidney Transplantation
Study to Evaluate the Safety and Efficacy of the 10 GE Xenokidney in Patients With ESRD
The purpose of this study is to evaluate the safety and efficacy of the 10 GE Xenokidney in patients with ESRD who are either not eligible for conventional allogeneic kidney transplantation (Group 1) or are on an Organ…
- Conditions
- ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
- Trial name
- EXPAND (NCT06878560)
- Testing
- 10 GE Xenokidney
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- United Therapeutics
Kidney Transplantation
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients
This study was to compare CFZ533 to tacrolimus (TAC) in prevention of organ rejection in kidney transplant.
- Trial name
- CIRRUS I (NCT03663335)
- Testing
- CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS)
- Where
- 74 sites in United States, Argentina and 18 more
- Volunteers
- 418 people
- Sponsor
- Novartis Pharmaceuticals
Kidney Transplantation
A Dose Escalation Study of TCD601 Compared to ATG in de Novo Renal Transplantation
The purpose of this study is to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of escalating doses of TCD601 when compared to rATG in de novo renal transplant patients.
- Trial name
- NCT06365437
- Testing
- TCD601, Tacrolimus (TAC), Corticosteroids (CS)
- Where
- 7 sites in Austria, Spain and 1 more
- Volunteers
- 33 people
- Sponsor
- ITB-Med LLC
Hematopoietic Stem Cell Transplantation, Cancer
Supportive Care Intervention for Outpatient Stem Cell Transplant Patients
The overall goal of this study is to assess the efficacy of the care.coach Avatar™ in improving anxiety and quality of life for patients undergoing outpatient transplant.
- Trial name
- NCT06564233
- Testing
- care.coach Avatar™
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Victor Wang
Kidney Transplantation
Study to Compare the Efficacy and Safety After Conversion to RaparoBell® or My-Rept® in Kidney Transplant Patients
The purpose of this study is to evaluate the efficacy and Safety after conversion to RaparoBell® or Myrept® in patients who in renal transplant patients undergoing maintenance therapy with Mycophenolic acid.
- Trial name
- NCT05193565
- Testing
- Sirolimus, Mycophenolate mofetil
- Where
- South Korea
- Volunteers
- 206 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Kidney Transplantation
A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)
The purpose of this study is to determine the optimal regimen for the use of siplizumab, a human anti-CD2 antibody, combined with donor bone marrow cells and non-myeloablative conditioning, for tolerance induction in living donor…
- Trial name
- NCT04803006
- Testing
- TCD601
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- ITB-Med LLC
Heart Transplantation
Study of Organ Perfusion in Heart Transplantation in Children
The goal of this prospective randomized single blind multicenter phase II study is to compare organ perfusion with Custodiol-N and Custodiol in heart transplantation in children of all ages (birth to <18 years) being listed on…
- Trial name
- NCT06032195
- Testing
- Custodiol-N, Custodiol
- Where
- 3 sites in Germany
- Volunteers
- 15 people
- Sponsor
- Dr. F. Köhler Chemie GmbH
Spinal Cord Injury, Safety
Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A Phase II Randomized Controlled Trial
Purpose: This clinical trial is studying an investigational cell therapy called XS228-a lab-made stem cell product designed to help repair damaged nerves in the spinal cord.
- Conditions
- Spinal Cord Injury, Safety, Efficacy, Clinical Trial
- Trial name
- NCT06974968
- Testing
- Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells
- Where
- China
- Volunteers
- 60 people
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Spinal Cord Injury, Safety
Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in Subacute Spinal Cord Injury: A Phase I Trial
This Phase I clinical trial is designed to evaluate the safety, tolerability of XS228 ( iPSC-Derived Motor Neuron Progenitor Cells) in patients with Subacute Spinal Cord Injury
- Conditions
- Spinal Cord Injury, Safety, Clinical Trials, Efficacy
- Trial name
- NCT06976229
- Testing
- Allogeneic Human Induced Pluripotent Stem Cell (iPSC)-Derived Motor Neuron Progenitor Cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.
Kidney Transplantation
A Study to Assess the Efficacy and Safety of ASKP1240 in de Novo Kidney Transplant Recipients
The purpose of this study is to evaluate the efficacy and safety of ASKP1240, an anti-CD40 monoclonal antibody, for the prophylaxis of organ rejection after kidney transplantation.
- Trial name
- NCT01780844
- Testing
- ASKP1240, Tacrolimus, Mycophenolate Mofetil (MMF)
- Where
- 42 sites in United States
- Volunteers
- 149 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Kidney Transplantation in Highly Sensitized Patients
Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
The goal of this follow-up study is to learn about long-term patient survival and graft function in highly sensitized patients who have received desensitization treatment with imlifidase or standard of care (SoC) in order to…
- Trial name
- ConfIdeSLTFU (NCT05714514)
- Testing
- Imlifidase administered in the ConfIdeS study, Best available treatment administered in the ConfIdeS study
- Where
- 14 sites in United States
- Volunteers
- 64 people
- Sponsor
- Hansa Biopharma AB